240 related articles for article (PubMed ID: 27468199)
21. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer.
Liu X; Fu Y; Chen Q; Wu J; Gao W; Jiang K; Miao Y; Wei J
BMC Gastroenterol; 2018 Nov; 18(1):168. PubMed ID: 30400836
[TBL] [Abstract][Full Text] [Related]
22. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
23. Long-term survival after resection of pancreatic cancer: a single-center retrospective analysis.
Yamamoto T; Yagi S; Kinoshita H; Sakamoto Y; Okada K; Uryuhara K; Morimoto T; Kaihara S; Hosotani R
World J Gastroenterol; 2015 Jan; 21(1):262-8. PubMed ID: 25574100
[TBL] [Abstract][Full Text] [Related]
24. Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer.
Boone BA; Sabbaghian S; Zenati M; Marsh JW; Moser AJ; Zureikat AH; Singhi AD; Zeh HJ; Krasinskas AM
J Surg Oncol; 2014 Aug; 110(2):171-5. PubMed ID: 24665063
[TBL] [Abstract][Full Text] [Related]
25. Resection of Borderline Resectable and Locally Advanced Pancreatic Adenocarcinomas after Neoadjuvant Chemotherapy.
Addeo P; Rosso E; Fuchshuber P; Oussoultzoglou E; De Blasi V; Simone G; Belletier C; Dufour P; Bachellier P
Oncology; 2015; 89(1):37-46. PubMed ID: 25766660
[TBL] [Abstract][Full Text] [Related]
26. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
[TBL] [Abstract][Full Text] [Related]
27. Utility of tumor markers in determining resectability of pancreatic cancer.
Schlieman MG; Ho HS; Bold RJ
Arch Surg; 2003 Sep; 138(9):951-5; discussion 955-6. PubMed ID: 12963650
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcome of portomesenteric vein invasion and prognostic factors in pancreas head adenocarcinoma.
Jeong J; Choi DW; Choi SH; Heo JS; Jang KT
ANZ J Surg; 2015 Apr; 85(4):264-9. PubMed ID: 24641800
[TBL] [Abstract][Full Text] [Related]
29. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer.
Akita H; Takahashi H; Ohigashi H; Tomokuni A; Kobayashi S; Sugimura K; Miyoshi N; Moon JH; Yasui M; Omori T; Miyata H; Ohue M; Fujiwara Y; Yano M; Ishikawa O; Sakon M
Eur J Surg Oncol; 2017 Jun; 43(6):1061-1067. PubMed ID: 28389044
[TBL] [Abstract][Full Text] [Related]
30. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
32. Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy.
Golcher H; Brunner T; Grabenbauer G; Merkel S; Papadopoulos T; Hohenberger W; Meyer T
Eur J Surg Oncol; 2008 Jul; 34(7):756-64. PubMed ID: 18191528
[TBL] [Abstract][Full Text] [Related]
33. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
34. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
35. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
36. [A result of surgical treatment for ductal adenocarcinoma of the head of the pancreas].
Moon HJ; Jang KT; Heo JS; Choi SH; Joh JW; Kim YI
Korean J Gastroenterol; 2003 Aug; 42(2):156-63. PubMed ID: 14532721
[TBL] [Abstract][Full Text] [Related]
37. Applicability of current NCCN Guidelines for pancreatic adenocarcinoma resectability: analysis and pitfalls.
Garces-Descovich A; Beker K; Jaramillo-Cardoso A; James Moser A; Mortele KJ
Abdom Radiol (NY); 2018 Feb; 43(2):314-322. PubMed ID: 29392370
[TBL] [Abstract][Full Text] [Related]
38. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?
Buc E; Couvelard A; Kwiatkowski F; Dokmak S; Ruszniewski P; Hammel P; Belghiti J; Sauvanet A
Eur J Surg Oncol; 2014 Nov; 40(11):1578-85. PubMed ID: 24923739
[TBL] [Abstract][Full Text] [Related]
39. Surgical management of pancreatic cancer--pancreaticoduodenectomy.
Donahue TR; Reber HA
Semin Oncol; 2015 Feb; 42(1):98-109. PubMed ID: 25726055
[TBL] [Abstract][Full Text] [Related]
40. Selection criteria in resectable pancreatic cancer: a biological and morphological approach.
Tamburrino D; Partelli S; Crippa S; Manzoni A; Maurizi A; Falconi M
World J Gastroenterol; 2014 Aug; 20(32):11210-5. PubMed ID: 25170205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
